Neuca

Neuca Forward P/E

The Forward P/E Ratio of Neuca (NEU.WA) as of Oct 23, 2026 is 22.86. In the previous year, Forward P/E Ratio was 23.06 — a change of -0.86% (lower).

Forward P/E

22.86

YoY

-0.86%

Last updated:

Forward P/E Ratio of Neuca is 2025 22.86 . Forward P/E Ratio of Neuca was 2024 23.06 . It decreases by -0.86% lower compared to the previous year.

The Neuca Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
36.19 PLN
Jan 1, 2019
30.23 PLN
Jan 1, 2020
25.08 PLN
Jan 1, 2021
23.60 PLN
Jan 1, 2022
25.91 PLN
Jan 1, 2023
24.31 PLN
Jan 1, 2024
23.06 PLN
Jan 1, 2025
22.86 PLN
The Neuca Forward P/E history
YEARForward P/EYoY
22.86-0.86%
23.06-5.17%
24.31-6.17%
25.91+9.78%
23.60-5.88%
25.08-17.02%
30.23-16.47%
36.19-3.84%
37.63+18.23%
31.83-9.35%
35.11-8.11%
38.21—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

Forward P/E Ratio of Neuca is 22.86 in 2025.

Forward P/E Ratio of Neuca changed from 23.06 to 22.86, representing a -0.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Neuca since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Neuca with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neuca

All Key Metrics — Neuca